摘要
目的评估布地奈德粉吸入剂治疗轻中度慢性持续期支气管哮喘的有效性和安全性。方法选择2011年4—5月就诊于我院呼吸科门诊符合入选条件的9例患者，使用布地奈德粉吸入剂（o．1mg／吸、3吸／次、2次／d），并按需使用沙丁胺醇气雾剂（0．1mg／吸，≤8吸／d）治疗3个月。结果哮喘控制测试平均分在治疗结束达到20分左右，与基线比较，差异具有统计学意义（P〈0．05）；治疗1个月后，患者的肺功能得到改善并在之后的治疗中继续升高；缓解药用量及症状评分在用药1个月后较基线有显著下降（P〈0．05），且在以后的治疗中持续下降（P〈0．05）；药物安全性较好。结论布地奈德粉吸入剂可有效改善轻中度持续期支气管哮喘患者的临床症状及肺功能，治疗后1个月哮喘即得到基本控制。因本研究样本量较少，肺功能指标未见统计学意义。
Objective To evaluate the clinical efficacy and safety ofbudesonide powder for inhalation on mild to moderate chronic persistent bronchial asthma. Methods 9 patients with bronchial asthma were selected from April to May in 2011. The patients received budesonide powder for inhalation at the dose of 0.1 mg per puff, 3 puffs each time, and twice a day for 3 months, and using salbutamol aerosol when needed（0.1 mg per puff, no more than 8 puffs a day）. Results After treatment, the asthma control test scores went up to 20, and it was significant comparing with the baseline（P〈0.05）. After treatment for 1 month, the patients＇ lung functions recovered obviously, and the recovery was continued. The salbutamol needs and asthmatic symptoms decreased significantly from the baseline after 1 month（P〈0.05）, and continued in the later treatment（P〈0.05）. Conclusion Budesonide powder for inhalation can improve the asthmatic symptoms and lung functions of mild to moderate chronic persistent bronchial asthmatic patients effectively and safely. The asthma was controlled generally after 1 month of treatment. There was no statisticant variations in terms of lung functions because of little sample.
出处
《中国实用乡村医生杂志》
2013年第15期38-40,共3页
Chinese Practical Journal of Rural Doctor
